Sinco Pharmaceuticals Holdings Limited

SEHK:6833 Stok Raporu

Piyasa değeri: HK$382.2m

Sinco Pharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Sinco Pharmaceuticals Holdings şirketinin toplam hissedar öz sermayesi CN¥644.7M ve toplam borcu CN¥327.3M olup, bu da borç-öz sermaye oranını 50.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥1.8B ve CN¥1.2B dir. Sinco Pharmaceuticals Holdings 'in FAVÖK'ü CN¥131.5M faiz karşılama oranı 158.6 dur. Şirketin CN¥282.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

50.8%

Borç/özkaynak oranı

CN¥327.33m

Borç

Faiz karşılama oranı158.6x
NakitCN¥282.01m
EşitlikCN¥644.70m
Toplam yükümlülüklerCN¥1.17b
Toplam varlıklarCN¥1.82b

Son finansal sağlık güncellemeleri

Recent updates

What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

Oct 04
What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Aug 16
Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08
Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26
A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26
Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25
I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10
Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24
Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11
How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6833 'nin kısa vadeli varlıkları ( CN¥1.3B ) kısa vadeli yükümlülüklerini ( CN¥1.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 6833 şirketinin kısa vadeli varlıkları ( CN¥1.3B ) uzun vadeli yükümlülüklerini ( CN¥29.9M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6833 'nin net borç/öz sermaye oranı ( 7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 6833 'nin borç/öz sermaye oranı son 5 yılda 369.6% seviyesinden 50.8% seviyesine düştü.

Borç Kapsamı: 6833 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 6833 'in borcuna ilişkin faiz ödemeleri EBIT ( 158.6 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.


Bilanço


Sağlıklı şirketleri keşfedin